John Smyth

1.6k total citations
49 papers, 1.2k citations indexed

About

John Smyth is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Smyth has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 17 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Smyth's work include Cancer therapeutics and mechanisms (7 papers), Ovarian cancer diagnosis and treatment (5 papers) and Cancer Treatment and Pharmacology (5 papers). John Smyth is often cited by papers focused on Cancer therapeutics and mechanisms (7 papers), Ovarian cancer diagnosis and treatment (5 papers) and Cancer Treatment and Pharmacology (5 papers). John Smyth collaborates with scholars based in United Kingdom, Netherlands and Belgium. John Smyth's co-authors include SP Langdon, T Sethi, Enrique Rozengurt, Hani Gabra, Frances R. Balkwill, Frances Burke, Lucy Wall, Caroline Barton, Heine H. Hansen and J. Renard and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Molecular Microbiology.

In The Last Decade

John Smyth

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Smyth United Kingdom 19 494 458 237 173 122 49 1.2k
Dennis Yi‐Shin Kuo United States 14 554 1.1× 456 1.0× 105 0.4× 48 0.3× 134 1.1× 42 1.2k
C. Sue Richards United States 20 934 1.9× 434 0.9× 394 1.7× 168 1.0× 127 1.0× 41 2.3k
Laith Dabbagh Canada 15 549 1.1× 546 1.2× 194 0.8× 111 0.6× 23 0.2× 23 1.3k
B A Ponder United Kingdom 25 1.1k 2.2× 745 1.6× 159 0.7× 204 1.2× 413 3.4× 39 2.7k
Paul R. Billings United States 29 522 1.1× 382 0.8× 193 0.8× 102 0.6× 54 0.4× 98 2.1k
Sebastian Häusler Germany 22 451 0.9× 530 1.2× 87 0.4× 67 0.4× 139 1.1× 38 1.4k
Sebastian Mayer United States 24 836 1.7× 643 1.4× 212 0.9× 162 0.9× 22 0.2× 111 2.0k
Robert Kubiak Poland 18 553 1.1× 206 0.4× 67 0.3× 154 0.9× 50 0.4× 77 1.1k
Patrícia Ashton‐Prolla Brazil 30 1.2k 2.5× 1.1k 2.3× 232 1.0× 206 1.2× 110 0.9× 158 2.9k
Frank Markland United States 9 426 0.9× 231 0.5× 105 0.4× 52 0.3× 256 2.1× 11 880

Countries citing papers authored by John Smyth

Since Specialization
Citations

This map shows the geographic impact of John Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Smyth more than expected).

Fields of papers citing papers by John Smyth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Smyth. The network helps show where John Smyth may publish in the future.

Co-authorship network of co-authors of John Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of John Smyth. A scholar is included among the top collaborators of John Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Smyth. John Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergmann, Lothar, Birge Berns, Angus Dalgleish, et al.. (2010). Investigator-initiated trials of targeted oncology agents: why independent research is at risk?. Annals of Oncology. 21(8). 1573–1578. 14 indexed citations
2.
Dangoor, Adam, Paul Lorigan, Ulrich Keilholz, et al.. (2009). Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunology Immunotherapy. 59(6). 863–873. 33 indexed citations
3.
Gourley, Charlie, Karen J. Taylor, Derek Anthony Scott, et al.. (2005). WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. International Journal of Oncology. 26(6). 1681–1689. 40 indexed citations
4.
Wall, Lucy, Frances Burke, Caroline Barton, John Smyth, & Frances R. Balkwill. (2003). IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro.. PubMed. 9(7). 2487–96. 85 indexed citations
5.
Twelves, Chris, Klaas Hoekman, A. Bowman, et al.. (2003). Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. European Journal of Cancer. 39(13). 1842–1851. 75 indexed citations
6.
Kesteren, Charlotte van, Chris Twelves, Angela Bowman, et al.. (2002). Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anti-Cancer Drugs. 13(4). 381–393. 38 indexed citations
7.
Smyth, John. (2001). La Autonomia Escolar: Una Perspectiva Critica. University of Huddersfield Repository (University of Huddersfield). 6 indexed citations
8.
Donnellan, Paul & John Smyth. (2001). Informed consent and randomised controlled trials.. PubMed. 46(2). 100–2. 3 indexed citations
9.
Smyth, John, Jan H.M. Schellens, Hilary Calvert, et al.. (2001). Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology. 12(4). 509–511. 26 indexed citations
10.
Bartlett, John M.S., K G Macleod, Eric P. Miller, et al.. (1999). Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. British Journal of Cancer. 79(7-8). 1098–1103. 16 indexed citations
11.
Cunningham, David, M. Dicato, Jaap Verweij, et al.. (1996). Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: Ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Annals of Oncology. 7(3). 277–282. 18 indexed citations
12.
Pavlidis, Nicholas, Axel‐R. Hanauske, Teresa Gamucci, et al.. (1996). A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG). Annals of Oncology. 7(5). 529–531. 37 indexed citations
13.
Cummings, Jeffrey L., et al.. (1993). Incorporation and Release of Chemically Intact Mitomycin C from Albumin Microspheres: a High Performance Liquid Chromatography Evaluation. Journal of drug targeting. 1(4). 317–324. 6 indexed citations
14.
Kaye, Stuart, Peter Harper, John Smyth, et al.. (1992). Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. British Journal of Cancer. 65(4). 624–625. 1 indexed citations
15.
Smyth, John. (1991). Una pedagogía crítica de la práctica en el aula. Revista de educación. 79(294). 275–300. 21 indexed citations
16.
Anderson, Gerald G., John Smyth, Giuseppe Giaccone, et al.. (1989). Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. European Journal of Cancer and Clinical Oncology. 25(5). 909–910. 8 indexed citations
17.
Capewell, Simon, Sharon Cameron, N J Douglas, et al.. (1987). Patients presenting with lung cancer in south east Scotland. Edinburgh Lung Cancer Group.. Thorax. 42(11). 853–857. 18 indexed citations
18.
Beer, M., Franco Cavalli, Stuart Kaye, et al.. (1987). A phase II study of carboplatin in advanced or metastatic stomach cancer. European Journal of Cancer and Clinical Oncology. 23(10). 1565–1567. 1 indexed citations
19.
Abele, R, M. Clavel, P. Dodion, et al.. (1987). The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. European Journal of Cancer and Clinical Oncology. 23(12). 1921–1924. 92 indexed citations
20.
Smyth, John, et al.. (1965). Behind the scenes at Wimbledon. St Martin's Press eBooks. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dennis Yi‐Shin Kuo Breakdown of academic impact, for papers by C. Sue Richards Breakdown of academic impact, for papers by Laith Dabbagh Breakdown of academic impact, for papers by B A Ponder Breakdown of academic impact, for papers by Paul R. Billings Breakdown of academic impact, for papers by Sebastian Häusler Breakdown of academic impact, for papers by Sebastian Mayer Breakdown of academic impact, for papers by Robert Kubiak Breakdown of academic impact, for papers by Patrícia Ashton‐Prolla Breakdown of academic impact, for papers by Frank Markland
Rankless by CCL
2026